Skip to main content

Animations

MJFF Publications

6201 - 6225 of 9148 Results
Title
Year
  • Year
  • 2015
  • 2022
  • 2021
  • 2025
  • 2006
  • 2021
  • 2016
  • 2018
  • 2009
  • 2026
  • 2011
  • 2015
  • 2018
  • 2005
  • 2018
  • 2014
  • 2016
  • 2013
  • 2006
  • 2017
  • 2017
  • 2020
  • 2017
  • 2022
  • 2021
  • Summary Details
    OPEN
    Title: Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson’s Disease via Protein Semisynthesis and Mutagenesis
    Journal Name: Journal of the American Chemical Society
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/ja5131726
    Citation Count: 166
  • Summary Details
    OPEN
    Title: Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's disease
    Journal Name: Neuropsychologia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108419
    Citation Count: 20
  • Investigating Cognitive Global Coordination in normal and autistic children using virtual reality environments – An EEG Study
    2021
    Summary Details
    RESTRICTED
    Title: Investigating Cognitive Global Coordination in normal and autistic children using virtual reality environments – An EEG Study
    Journal Name: 2021 10th International IEEE/EMBS Conference on Neural Engineering (NER)
    Publisher: IEEE
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1109/ner49283.2021.9441259
    Citation Count: 4
  • Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease
    2025
    Summary Details
    RESTRICTED
    Title: Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.107947
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro
    Journal Name: Experimental Cell Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.yexcr.2006.03.012
    Citation Count: 136
  • Summary Details
    OPEN
    Title: Pharmacological validation of TDO as a target for Parkinson’s disease
    Journal Name: The FEBS Journal
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/febs.15721
    Citation Count: 29
  • Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA
    2016
    Summary Details
    RESTRICTED
    Title: Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA
    Journal Name: Analytical and Bioanalytical Chemistry
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s00216-016-9863-7
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-171248
    Citation Count: 308
  • Summary Details
    OPEN
    Title: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0b013e3181c29356
    Citation Count: 430
  • Summary Details
    OPEN
    Title: SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neurot.2026.e01049
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(11)70175-2
    Citation Count: 344
  • Summary Details
    OPEN
    Title: Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26170
    Citation Count: 307
  • Summary Details
    OPEN
    Title: The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20180248
    Citation Count: 219
  • Summary Details
    OPEN
    Title: Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone
    Journal Name: Toxicological Sciences
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/toxsci/kfi304
    Citation Count: 270
  • Summary Details
    OPEN
    Title: Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.27361
    Citation Count: 205
  • Summary Details
    OPEN
    Title: Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-sa
    DOI - Digital Object Identifier: 10.1016/j.nbd.2014.06.009
    Citation Count: 227
  • Summary Details
    OPEN
    Title: Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20160557
    Citation Count: 182
  • Summary Details
    OPEN
    Title: Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
    Journal Name: PLoS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc0
    DOI - Digital Object Identifier: 10.1371/journal.pone.0080705
    Citation Count: 187
  • Crossroads in GDNF therapy for Parkinson's disease
    2006
    Summary Details
    RESTRICTED
    Title: Crossroads in GDNF therapy for Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.20861
    Citation Count: 174
  • Summary Details
    OPEN
    Title: Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20170803
    Citation Count: 179
  • Summary Details
    OPEN
    Title: Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20170802
    Citation Count: 166
  • Summary Details
    OPEN
    Title: Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2020.4725
    Citation Count: 146
  • Summary Details
    OPEN
    Title: Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000004609
    Citation Count: 152
  • Summary Details
    OPEN
    Title: Six Action Steps to Address Global Disparities in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2022.1783
    Citation Count: 144
  • Summary Details
    OPEN
    Title: Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28738
    Citation Count: 116
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.